secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2022-05-09T23:59:59+00:00
Accession:  0001564590-22-018892
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax Q1 2022 net loss $37.2M; cash $397.9M; clinical milestones on track for 2023
--------------------------------------------------------------------------------

- Net loss $37.2M ($0.63/sh) vs $27.7M ($0.54) in Q1 2021; R&D spend $30.0M vs $21.9M.
- Cash, cash equivalents and short-term investments $397.9M; 59M shares and equivalents outstanding.
- FY2022 guidance: R&D $130-140M, total opex $160-170M; Q2 opex $38-42M.
- Revumenib: AUGMENT-101 enrollment completion expected later 2022; topline data 1H23; combination trials underway.
- Axatilimab: FDA Fast Track for cGVHD; AGAVE-201 topline data 1H23; potential BLA filing 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022018892/0001564590-22-018892-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000156459022018892/sndx-8k_20220509.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-018892

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer